Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MYGN

Myriad Genetics, Inc

Sep 12 • 04:00PM ET

7.24

-0.44 -5.73 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH INCY QGEN EXAS NTLA CRSP CDNA TXG TWST

| Held by: IJR IWM XBI VTI IJS IWN SPSM SLYV IBB VB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.28	Insider Own	5.04%	Shs Outstand	93.10M	Perf Week	9.53%
Market Cap	673.64M	Forward P/E	78.03	EPS next Y	0.09	Insider Trans	0.00%	Shs Float	88.36M	Perf Month	23.34%
Enterprise Value	753.84M	PEG	-	EPS next Q	-0.01	Inst Own	97.96%	Short Float	10.17%	Perf Quarter	39.50%
Income	-395.20M	P/S	0.81	EPS this Y	-96.16%	Inst Trans	-3.18%	Short Ratio	5.21	Perf Half Y	-25.36%
Sales	832.90M	P/B	1.74	EPS next Y	1625.50%	ROA	-44.85%	Short Interest	8.99M	Perf YTD	-47.19%
Book/sh	4.17	P/C	9.05	EPS next 5Y	14.09%	ROE	-70.03%	52W High	29.30 -75.29%	Perf Year	-73.22%
Cash/sh	0.80	P/FCF	-	EPS past 3/5Y	-59.13% -	ROIC	-83.32%	52W Low	3.76 92.55%	Perf 3Y	-66.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	6.64% -0.32%	Gross Margin	68.05%	Volatility	7.33% 6.07%	Perf 5Y	-41.57%
Dividend TTM	-	EV/Sales	0.91	EPS Y/Y TTM	-137.31%	Oper. Margin	-9.21%	ATR (14)	0.41	Perf 10Y	-80.95%
Dividend Ex-Date	-	Quick Ratio	1.28	Sales Y/Y TTM	3.83%	Profit Margin	-47.45%	RSI (14)	65.47	Recom	3.29
Dividend Gr. 3/5Y	- -	Current Ratio	1.42	EPS Q/Q	-782.00%	SMA20	13.72%	Beta	1.97	Target Price	7.17
Payout	-	Debt/Eq	0.40	Sales Q/Q	0.76%	SMA50	30.23%	Rel Volume	0.99	Prev Close	7.68
Employees	2700	LT Debt/Eq	0.22	Earnings	Aug 05 AMC	SMA200	-17.72%	Avg Volume	1.73M	Price	7.24
IPO	Oct 06, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	741.03% 5.57%	Trades		Volume	1,712,397	Change	-5.73%

Date	Action	Analyst	Rating Change	Price Target Change
May-21-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$6
May-08-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$6
Apr-09-25	Downgrade	Guggenheim	Buy → Neutral
Mar-12-25	Upgrade	Piper Sandler	Neutral → Overweight	$11.50 → $12.50
Feb-12-25	Initiated	Craig Hallum	Buy	$29
Dec-10-24	Initiated	UBS	Neutral	$18
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$30 → $21
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight	$32
Aug-28-24	Initiated	Wells Fargo	Overweight	$35
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$29
Jun-03-24	Resumed	Jefferies	Underperform	$20
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform	$25 → $35
Dec-21-23	Resumed	Piper Sandler	Neutral	$23
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$20
Dec-14-23	Initiated	Guggenheim	Buy	$23
Dec-13-23	Initiated	Wolfe Research	Outperform	$28
Jul-05-23	Resumed	JP Morgan	Underweight	$18
May-23-23	Upgrade	Goldman	Sell → Buy	$18 → $25
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$25

Show Previous Ratings

Sep-08-25 08:14AM	MYGN Stock Might Gain on The Lancet Study Backing Precise MRD (Zacks)
Sep-05-25 10:56AM	MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain? (Zacks)
12:39AM	3 Russell 2000 Stocks with Open Questions (StockStory)
Sep-04-25 07:00PM	Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology (GlobeNewswire)
Sep-03-25 04:30PM	New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression (GlobeNewswire)
04:05PM	Loading…
Aug-27-25 04:05PM	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
Aug-20-25 02:00AM	ANGLE Announces Collaboration with Myriad Genetics (ACCESSWIRE)
Aug-18-25 08:30AM	Myriad Genetics Appoints Ben Wheeler Chief Financial Officer (GlobeNewswire)
12:36AM	3 Healthcare Stocks We're Skeptical Of (StockStory)
Aug-13-25 08:00AM	New Myriad Genetics Survey Uncovers Women Fear Screenings-But Feel Reassured by the Results (GlobeNewswire)
12:11AM	Myriad Genetics's Q2 Earnings Call: Our Top 5 Analyst Questions (StockStory)
12:10AM	MYGN Q2 Deep Dive: Oncology Strategy Shift and Product Execution Shape Guidance (StockStory)
Aug-12-25 10:00AM	RxPreferred Benefits Expands Executive Leadership Team with Strategic Appointment and Key Promotions (PR Newswire)
12:03AM	3 Reasons MYGN is Risky and 1 Stock to Buy Instead (StockStory)
Aug-11-25 07:45AM	TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN) (Insider Monkey)
04:57PM	Loading…
Aug-06-25 04:57PM	CareDx Announces Appointment of Nathan Smith as Chief Financial Officer (Business Wire) +46.51% +7.58%
01:11PM	Why Is Myriad Genetics (MYGN) Stock Soaring Today (StockStory)
Aug-05-25 06:30PM	Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics (Zacks)
05:55PM	Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:52PM	Myriad: Q2 Earnings Snapshot (Associated Press Finance)
04:48PM	Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6% (StockStory)
04:05PM	Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum (GlobeNewswire)
Aug-03-25 11:13PM	Earnings To Watch: Myriad Genetics (MYGN) Reports Q2 Results Tomorrow (StockStory)
Jul-31-25 08:30AM	Myriad Genetics Announces New $200 Million Credit Facility (GlobeNewswire) -5.19%
Jul-29-25 04:05PM	Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire) -6.39%
02:26PM	Why Myriad Genetics (MYGN) Shares Are Falling Today (StockStory)
04:31AM	North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers (GlobeNewswire)
Jul-15-25 09:00AM	Myriad Genetics Earns 2025 Great Place To Work Certification (GlobeNewswire)
Jul-07-25 09:55AM	Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches (Zacks) -5.54%
Jun-27-25 05:22AM	5 Revealing Analyst Questions From Myriad Genetics's Q1 Earnings Call (StockStory)
08:25AM	Loading…
Jun-16-25 08:25AM	Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? (Zacks)
Jun-06-25 09:09AM	Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape? (Zacks)
12:01AM	3 Reasons to Avoid MYGN and 1 Stock to Buy Instead (StockStory)
Jun-05-25 11:31AM	Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? (Zacks) -6.99%
Jun-03-25 09:00AM	Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen (GlobeNewswire) +9.42%
Jun-02-25 09:00AM	Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types (GlobeNewswire) +6.44%
May-27-25 07:53PM	Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025 (Insider Monkey) +6.14%
04:05PM	Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting (GlobeNewswire)
May-26-25 11:34PM	Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 (StockStory)
May-19-25 09:58AM	MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp (StockStory) +7.26%
May-14-25 04:45PM	Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences (GlobeNewswire) -6.57% +7.03%
May-09-25 04:07AM	Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins' Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 09:35AM	Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround (Zacks) -5.62%
May-07-25 04:30PM	Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology (GlobeNewswire) -41.27%
08:34AM	MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook (Zacks)
03:19AM	Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
May-06-25 11:35PM	Myriad genetics lowers 2025 revenue guidance by $35M amid GeneSight challenges (Seeking Alpha) -5.58%
11:35PM	Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:30PM	Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance (GlobeNewswire)
May-02-25 12:58AM	Myriad Genetics: Significantly Undervalued With Profitability In Sight (Seeking Alpha) +6.03%
12:39AM	3 Unprofitable Stocks Walking a Fine Line (StockStory)
May-01-25 12:34AM	1 Unprofitable Stock to Target This Week and 2 to Be Wary Of (StockStory)
Apr-30-25 08:00AM	Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor (GlobeNewswire)
Apr-29-25 09:00AM	Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 (GlobeNewswire)
Apr-25-25 04:05PM	Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting (GlobeNewswire)
09:16AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-22-25 10:10AM	Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside? (Zacks)
Apr-21-25 04:05PM	Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing (GlobeNewswire)
Apr-15-25 10:02AM	Myriad Genetics price target lowered to $9 from $11 at BofA (TipRanks)
Apr-08-25 04:15PM	Myriad Genetics Announces Inducement Awards (GlobeNewswire) +9.31%
Apr-07-25 08:00AM	Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer (GlobeNewswire)
Mar-28-25 08:56AM	Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? (Zacks)
Mar-26-25 11:30AM	Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? (Zacks) -5.34%
Mar-25-25 10:45AM	Allspring Small Company Growth Fund Q4 2024 Commentary (SeekingAlpha)
Mar-21-25 08:30AM	Artisan International Small-Mid Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:05AM	A Look Back at Therapeutics Stocks Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack (StockStory)
Mar-17-25 05:10AM	Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Mar-12-25 01:17PM	Why Are Myriad Genetics (MYGN) Shares Soaring Today (StockStory)
Mar-11-25 05:03AM	Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks (StockStory) +6.77%
Mar-04-25 04:03AM	Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 (StockStory)
Feb-27-25 04:15PM	Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools (GlobeNewswire)
Feb-25-25 02:07PM	Why Myriad Genetics (MYGN) Shares Are Plunging Today (StockStory) -14.80%
10:25AM	Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer (Insider Monkey)
07:59AM	Q4 2024 Myriad Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
02:03AM	Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-24-25 07:00PM	Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:00PM	Myriad Genetics (MYGN) Meets Q4 Earnings Estimates (Zacks)
05:11PM	Myriad: Q4 Earnings Snapshot (Associated Press Finance)
04:31PM	Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops (StockStory)
04:05PM	Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth (GlobeNewswire)
04:05PM	Myriad Genetics Announces Senior Leadership Transition (GlobeNewswire)
08:30AM	Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio (GlobeNewswire)
Feb-23-25 08:01AM	What To Expect From Myriad Geneticss (MYGN) Q4 Earnings (StockStory)
Feb-19-25 08:30AM	Myriad Genetics Included in Forbes America's Best Employers 2025 List (GlobeNewswire)
Feb-18-25 08:30AM	Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 (GlobeNewswire)
Feb-17-25 06:05AM	3 Reasons to Sell MYGN and 1 Stock to Buy Instead (StockStory)
Feb-06-25 08:30AM	Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test (GlobeNewswire)
Feb-05-25 04:15PM	Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay (GlobeNewswire)
08:30AM	Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration (GlobeNewswire)
Jan-29-25 08:30AM	Myriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference (GlobeNewswire)
Jan-24-25 08:08PM	Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now? (Insider Monkey)
Jan-23-25 08:30AM	Myriad Genetics Introduces Online Prenatal Genetic Testing Resource (GlobeNewswire)
Jan-21-25 08:30AM	Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology (GlobeNewswire)
Jan-15-25 08:30AM	Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance (GlobeNewswire)
Jan-09-25 04:30PM	Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History (GlobeNewswire)
Jan-08-25 11:27AM	UPDATE Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:00AM	Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 08:00AM	MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad's molecular residual disease assay (GlobeNewswire)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DIAZ PAUL J	President and CEO	Oct 11 '24	Sale	22.93	15,000	343,950	962,378	Oct 11 05:23 PM
DIAZ PAUL J	Officer	Oct 11 '24	Proposed Sale	22.93	15,000	343,950		Oct 11 10:35 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MYGN

Myriad Genetics, Inc

Upgrade your FINVIZ experience